Race Receives Positive Guidance on Zantrene via Pre-IND Meeting with US FDA

23 Nov
Nov , 23 , 2022 Daniel Tillett
Race-Receives-Positive-Guidance-on-Zantrene-via-Pre-IND-Meeting-with-US-FDADownload
LinkedIn

Related posts:

Danny Sharp appointed an Independent Non-Executive Director of Race Race Oncology Investor Presentation 2021Race Oncology Investor Presentation November 2021 Race Oncology reveals breakthrough chemotherapy heart protection discovery for Zantrene